COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report

Our case highlights SARS-CoV-2 and pembrolizumab as trigger of secondary hemophagocytic lymphohistiocytosis. Although it is a rare complication, it must be suspected in order to start specific treatment. In this context, intravenous immunoglobulins could be a therapeutic option.

Detalles Bibliográficos
Autores principales: Ramos-Ruperto, Luis, Busca-Arenzana, Carmen, Valdivieso, Juan, López-Granados, Eduardo, Robles-Marhuenda, Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017431/
https://www.ncbi.nlm.nih.gov/pubmed/33824942
http://dx.doi.org/10.1007/s42399-021-00882-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017431/
https://www.ncbi.nlm.nih.gov/pubmed/33824942
http://dx.doi.org/10.1007/s42399-021-00882-8

Ejemplares similares